Bradley Pharmaceuticals — Proxy Contest (October 2006)
52 slides from Bradley Pharmaceuticals's proxy contest presentation, Oct 13, 2006
Slide 1: New Horizons, New Accomplishments
New Horizons, New Accomplishments &} BRADLEY PHARMACEUTICALS, INC.
Slide 2: Presentation to Institutional Shareholder Services
2 Institutional Shareholder Services October 13, 2006 Bradley Pharmaceuticals, Inc. Presentation to:
Slide 3: Forward-Looking Statements
Forward-Looking Statements 3 This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that Bradley expects, believes or anticipates
Slide 4: Introduction: Bradley Board and Senior Management
Introduction Bradley Board of Directors Bradley Senior Management 4 In attendance are: Brent Lenczycki Vice President and Chief Financial Officer Leonard S. Jacob, M.D., Ph.D. Chairman, Nominating and Corporate Governance Committee Daniel Glassman President, CEO and Chairman of the Board
Slide 5: Company Overview
Company Overview 5 Specialty pharmaceutical company In-license, develop and bring to market patent-protected pharmaceuticals Create dynamic brands, leveraging core expertise of aggressive, targeted marketing and sales Target specialties include : Dermatology Podiatry Gastroenterology OB/GYN Committe
Slide 6: Company Overview
Company Overview 6 History 1985: Founded by Daniel Glassman, Chairman, President and CEO 1991: Company shares list on the NASDAQ via public offering 2003: Company lists on the NYSE: BDY Headquarters Fairfield, New Jersey Employees 311, including 173 Sales Representatives* * As of September 30, 2006
Slide 7: Company Overview
Company Overview 7 Dermatologic and Podiatric Brands 125 Sales Representatives* 74.8% of Net Sales** * As of September 30, 2006 ** Quarter ended June 30, 2006 Gastrointestinal, Nutritional and Women’s Health brands 48 Sales Representatives* 25.2% of Net Sales** Authorized Generic Versions of Doak &
Slide 8: Major Brands - Doak
Major Brands - Doak Adoxa ® Zoderm ® Rosula ® 8 Solaraze ® Gel Keralac™ Carmol ® 40 Zonalon ® LidaMantle ® Total Net Sales by Category for the 6 mos. ended June 30, 2006 as a percent of total Net Sales for the same period Source: Form 10-Q for Quarter Ended June 30, 2006
Slide 9: Major Brands - Kenwood
Major Brands - Kenwood Entsol ® / Brontex ® Deconamine ® /Tyzine ® 9 Pamine ® AnaMantle ® HC Flora-Q ® Total Net Sales by Category for the 6 mos. ended June 30, 2006 as a percent of total Net Sales for the same period Source: Form 10-Q for Quarter Ended June 30, 2006 All Others
Slide 10: Strategically Expanding From…
Strategically Expanding From… 10 Acquire the rights to products through acquisition and mergers with other specialty pharmaceutical companies Enhance product brands by extending the lifecycle of existing drugs and introducing product line extensions Grow through focused, aggressive marketing and tar
Slide 11: Strategically Expanding To…
Strategically Expanding To… 11 Bring to Market patent-protected brands positioned to fill unmet medical needs, and leverage Bradley’s marketing & sales expertise to deliver long-term shareholder value In-License phase II and phase III drugs with long- term intellectual property protection Develop pr
Slide 12: Bradley Financial Snapshot: Net Sales Full Years
Bradley Financial Snapshot 12 Net Sales – 3 Full Years Millions
Slide 13: Bradley Financial Snapshot: Net Sales 2005 vs. 2006
Bradley Financial Snapshot 13 Net Sales 2005 vs. 2006 Millions
Slide 14: Bradley Financial Snapshot: Net Income Full Years
Bradley Financial Snapshot 14 Net Income – 3 Full Years Millions
Slide 15: Bradley Financial Snapshot: Net Income 2005 vs. 2006
Bradley Financial Snapshot 15 Net Income - 2005 vs. 2006 * * Includes an R&D expense for the initial payment to MediGene AG of $5.0 million and a share-based compensation charge of $927,000 ** Includes a share-based compensation charge of $922,000. *** Includes a research and development expense for
Slide 16: Key Success Factors: Team Bradley
Key Success Factors 16 Team Bradley Name Title Experience (yrs) Daniel Glassman Chairman of the Board, President and CEO Brent Lenczycki VP, Chief Financial Officer Bradley Glassman Sr. VP, Sales & Marketing Alan Goldstein VP, Corporate Development Ralph Landau, Ph.D. VP, Chief Scientific Officer Wi
Slide 17: Key Success Factors: Synergistic Promotional Plan/Execution
Key Success Factors 17 Synergistic Promotional Plan/Execution
Slide 18: Merger/Acquisition/Co-Marketing Activity
Key Success Factors 18 Merger/Acquisition/Co-Marketing Activity – Last 5 Yrs Merger/Acquisition/Co-Marketing Activity – Prior Com pany Transaction Adams R espiratory ENTSOL ® MediGene Polyphenon ® E Lundbeck Flora-Q ® Dermik Benzamycin ® , Klaron ® , Noritate ® Com pany Transaction Mission Pharmacal
Slide 19: Expanded Initiatives to Increase Shareholder Value
& BRADLEY PHARMACEUTICALS, INC. SS. Expanded Initiatives to Increase Shareholder Value
Slide 20: Increasing Shareholder Value
Increasing Shareholder Value 20 Our Board and Senior Management initiated a plan earlier this year to enhance long-term shareholder value by: Improving and Expanding Product Offerings. Strengthening Our Financial Profile. Increasing Alignment with Shareholders’ Interests. Focusing Intensely on Opera
Slide 21: Improve and Expand Product Offerings
Increasing Shareholder Value 21 Improve and Expand Product Offerings. In-License phase II and III drugs. Develop and bring to market products with long-term intellectual property protection. Expand existing partnerships and joint venture relationships. Foster new strategic alliances that deliver a s
Slide 22: Strengthen Financial Profile
Increasing Shareholder Value 22 Strengthen Financial Profile Continue to remediate all material weaknesses previously disclosed. Implementing Information Technology controls, policies and procedures. Financial closing process : Recruited Director of Finance responsible for overseeing the financial c
Slide 23: Increase Alignment with Shareholders' Interests
Increasing Shareholder Value 23 Increase Alignment with Shareholders’ Interests Actively explore initiatives to improve shareholder value. Continue to communicate the Company’s existing strategic plan in appropriate forums: Industry analyst conferences. Quarterly earnings conference calls. Amended C
Slide 24: Focus Intensely on Operations
Increasing Shareholder Value 24 Focus Intensely on Operation Improve performance across Field Sales Force: Establish enhanced goals and actions. Improve training and accountability through field operations.
Slide 25: Proxy Contest
& BRADLEY PHARMACEUTICALS, INC. Proxy Contest
Slide 26: Proxy Contest - Overview
Proxy Contest - Overview 26 Costa Brava has filed a proxy statement nominating three people to be added to the Company’s Board and presenting several proposals. It has also issued other communications to Bradley shareholders. Costa Brava has criticized strategic steps taken by Bradley’s Management T
Slide 27: Proxy Contest - Overview
Proxy Contest - Overview 27 Costa Brava, its leader, Seth Hamot, and its other nominees have little public company board experience and no experience in the specialty pharmaceutical industry. Costa Brava is a $125M hedge fund that has no track record of increasing shareholder value. We believe that
Slide 28: Proxy Contest - Overview
Proxy Contest - Overview 28 The proxy fight to date demonstrates that the Costa Brava nominees will not be able to work effectively with our Board & Management Team. We are asking our shareholders to support Bradley’s Board of Directors and Management Team.
Slide 29: Board Nominees - Bradley
Board Nominees - Bradley Bradley Pharmaceuticals, Inc. Nominees 29 Board member since February 2006, brings almost 30 years of public accounting experience to Bradley. Executive Vice President and Chief Financial Officer of Computer Horizons Corporation before serving as its President and CEO from M
Slide 30: Board Nominees - Costa Brava
Board Nominees – Costa Brava Costa Brava Nominees 30 Currently is a consultant to a few small companies in the pharmaceutical industry, some of whom might represent a conflict of interest with Bradley. Past consultant and part-time employee at Cardinal Health Has not been a full-time employee at Car
Slide 31: Board Nominees - Summary
Board Nominees – Summary Costa Brava Nominees Bradley Pharmaceuticals, Inc. Douglas Linton John Ross Seth Hamot William J. Murphy Thomas Stagnaro Robert Whitehead Qualifications 31 NO NO NO NO YES YES Pharmaceutical Marketing Experience NO YES NO NO NO NO Primary Occupation – Residential Painting Se
Slide 32: Bradley Governance
Bradley Governance 32 Bradley is committed to continuously improving governance to meet all regulatory requirements. To enhance corporate governance in response to our dramatic growth, in February 2006, we added to our Board: Mr. William Murphy, CPA, to serve as a member, and now Chair, of the Board
Slide 33: Bradley Governance
Bradley Governance 33 Following the Annual Meeting: Seven of the Company’s eight directors will be independent under SEC and NYSE corporate governance standards. Half of the Company’s eight directors will represent new voices since the beginning of 2006. Each of the Board’s Audit Committee, Compensa
Slide 34: Bradley Governance
Bradley Governance 34 Our Audit Committee includes two audit committee financial experts. Non-management directors meet in executive sessions to discuss such topics as they determine. Costa Brava criticizes our governance but its nominees refused to meet with our Nominating Committee. Its nominees w
Slide 35: Costa Brava Assertions: Lease
Costa Brava Assertions 35 Costa Brava’s claim that our lease is a “conflict of interest” is just simply wrong In connection with the Board’s annual review of our Form 10-K, in which we have always disclosed the lease for our executive offices, and as part of its oversight obligations, the Company an
Slide 36: Costa Brava Assertions: Compensation
Costa Brava Assertions 36 Costa Brava’s claim that director and executive management compensation was excessive is wrong The compensation of our board members was set by the Compensation Committee based upon a report from a leading independent compensation consultant. In preparing the report, the co
Slide 37: Costa Brava Assertions: Compensation
Costa Brava Assertions 37 Costa Brava’s claim that director and executive management compensation was excessive is wrong Contrary to Costa Brava’s claim, from 2003 to 2005, Daniel Glassman’s compensation decreased by 25%, Brad Glassman’s decreased by 19% and Ralph Landau’s decreased by 10%. Brent Le
Slide 38: Costa Brava Assertions: Doesn't Understand Our Business
Costa Brava Assertions 38 Costa Brava doesn’t understand our business Misunderstands our business model and inventory and reserve requirements. Misunderstands our industry. Offers superficial and unrealistic operational suggestions, such as attending conventions and trade association functions. Offe
Slide 39: Proposal to Split Chairman and CEO
Costa Brava Proposals 39 Proposal to Split Position of Chairman and CEO Costa Brava’s proposal that Bradley should split the Chairman and CEO roles is contrary to customary practice at publicly traded healthcare companies. At eight of the ten biggest U.S. healthcare companies, the same executive ser
Slide 40: Proposal to Split Chairman and CEO
Costa Brava Proposals 40 Proposal to Split Position of Chairman and CEO We strongly believe that such a separation is not right for Bradley. Separation will create disruption, instability and a lack of continuity in a Management Team that has a history of delivering revenue growth and profits. This
Slide 41: Proposal to Recommend a Recapitalization
Costa Brava Proposals 41 Proposal to Recommend a Recapitalization Transaction Costa Brava’s proposal to recommend a recapitalization transaction is not in the best interests of shareholders. Dual class structure promotes: Stability and continuity in leadership and management Focus on long-term objec
Slide 42: Proposal Requesting Reimbursement of Solicitation Expenses
Costa Brava Proposals 42 Proposal Requesting Reimbursement of Solicitation Expenses if any Costa Brava Nominees are Elected: The Board believes that Costa Brava’s slate of nominees would not be in the best interests of the Company. Therefore, Costa Brava should not be reimbursed for its solicitation
Slide 43: Summary of Issues
Summary of Issues 43 The election of Messrs. Murphy, Stagnaro and Whitehead will benefit ALL Bradley shareholders: New, Independent and Qualified Voices Strong Specialty Pharmaceutical Experience Strong Accounting Experience
Slide 44: Summary of Issues
Summary of Issues 44 The slate of Costa Brava nominees is not qualified. No specialty pharmaceutical company experience. Virtually no public company board experience. No public accounting experience. Costa Brava is a small ($125M), activist hedge fund driven by self-interest. Despite a questionable
Slide 45: Summary of Issues
Summary of Issues 45 Costa Brava has little relevant experience to the Bradley proxy situation. Particular attention should be paid to TechTeam Global, the only other company where Costa Brava has won board presence, replacing half the previous board members: Since a settlement was reached in May 20
Slide 46: Summary of Issues
Summary of Issues 46 Costa Brava needs to explain to Bradley shareholders: What companies have benefited from their guidance/leadership? How has any company benefited from Costa Brava’s investment and oversight? Why are they nominating a self-interested voting clique to protect their interests and n
Slide 47: Summary of Issues
Summary of Issues 47 Costa Brava refuses to recognize our accomplishments. They have ignored the remarkable job Bradley has done to preserve prescription demand for its brands, in light of intense generic competition. Costa Brava is trying to take credit for Bradley’s success. They claim they are re
Slide 48: Summary of Issues
Summary of Issues 48 Costa Brava is attacking the Board and Management of a successful company with a strong track record Bradley has averaged annual Net Sales growth of 50% since 2000. Bradley has posted annual net profits for 5 consecutive years. Bradley’s stock value has significantly out-perform
Slide 49: Why Bradley
Why Bradley 49 Bradley averaged annual Net Sales growth of 50% since 2000 and has posted annual Net Profits for five consecutive years. $ in Millions
Slide 50: Why Bradley: Stock Performance vs. Peers
Why Bradley LTM 9/15/05 – 10/10/06 1/1/06 – 10/10/06 Change in Value Change in Value Company 50 -5.97% -3.52% Specialty Pharmaceutical Company Avg . (per Company, excluding Bradley) -3.03% 9.25% Valeant Pharmaceuticals (VRX) -5.57% -1.17% Sepracor Inc. (SEPR) -0.78% 18.02% Sciele Pharma (SCRX) -33.1
Slide 51: Additional Information
Additional Information 51 On September 29, 2006, Bradley filed with the SEC and began mailing to its stockholders a notice of annual meeting and a definitive proxy statement, together with a WHITE proxy card that can be used to elect our independent director nominees and to vote upon all the proposa
Slide 52: New Horizons, New Accomplishments
New Horizons, New Accomplishments &} BRADLEY PHARMACEUTICALS, INC.
Bradley Pharmaceuticals — Proxy Contest (October 2006) on 6ix